Free Review Articles on Mammary gland (Neoplasia)                                 Metatextbook

Freie Reviews über Brustdruese (Neubildung)                                 Look here for Journal Homepages

  • Mammary gland (Neoplasia)
  • Ovary (Neoplasia)
  • Ixabepilone
  • Trastuzumab
  • Exemestane
  • Lapatinib
  • Paclitaxel
  • Docetaxel
  • Steroid sulfatase
  • Neoplasia (Inherited)
  • Lymph node (Metastasis and sentinel)
  • BRCA
  • Mammary gland (MRT)
  • Gynecomastia
  • MET
  • Neoplasia (Carcinogenesis)
  • IGF1
  • Growth hormone
  • PARP
  • AMP activated protein kinase
  • Metformin
  • UFT
  • Bruxism
  • Stem cell (Neoplasia)
  • Colon and rectum (Neoplasia)
  • Capecitabine
  • Microendoscopy
  • Epirubicin
  • Preventive surgery
  • Laboratory medicine
  • HER2
  • Zinc
  • Transporter (Zinc)
  • SLC39A6
    • Nr.Year

    OPEN

    		Titleusers

    say

    		rate

    good

    		rate

    bad

    no link

    		Citation
    11990Carcinoma of the male breast: a review of 41 cases.



    		+-nlSouth Med J 83(10):1162-7 (1990)
    22008Hereditary breast and ovarian cancers.



    		+-nlCan Fam Physician 54(12):1691-2 (2008) Carroll JC
    32002Radiation treatment for breast cancer. Recent advances.



    		+-nlCan Fam Physician 48(-):1065-9 (2002)
    42010Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.



    		+-nlDtsch Arztebl Int 107(6):85-91 (2010) Gerber B
    52007Breast cancer (non-metastatic).



    		+-nlClin Evid (Online) 2007(): (2007) Stebbing J
    62009HER2 breast cancer therapies: a review.



    		+-nlBiologics 3():289-301 (2009) Murphy CG
    72008Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.



    		+-nlBiologics 2(3):505-15 (2008) Puhalla S
    82007Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.



    		+-nlBiologics 1(3):229-39 (2007) Henson ES
    92007Trastuzumab in the management of early and advanced stage breast cancer.



    		+-nlBiologics 1(1):19-31 (2007) Bartsch R
    102008Exemestane in early breast cancer: a review.



    		+-nlTher Clin Risk Manag 4(6):1295-304 (2008) Untch M
    112008Long-term safety of aromatase inhibitors in the treatment of breast cancer.



    		+-nlTher Clin Risk Manag 4(1):189-204 (2008) Nabholtz JM
    122007A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.



    		+-nlTher Clin Risk Manag 3(4):665-73 (2007) Nelson MH
    132009The use of paclitaxel in the management of early stage breast cancer.



    		+-nlHealth Technol Assess 13 Suppl 1():15-22 (2009) Griffin S
    142009Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.



    		+-nlHealth Technol Assess 13 Suppl 1():7-13 (2009) Chilcott J
    152009Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.



    		+-nlHealth Technol Assess 13 Suppl 1():1-6 (2009) Ward S
    162007Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.



    		+-nlHealth Technol Assess 11(40):1-144 (2007) Ward S
    172007Hormonal therapies for early breast cancer: systematic review and economic evaluation.



    		+-nlHealth Technol Assess 11(26):iii-iv, ix-xi, 1-134 (2007) Hind D
    182006Papillary carcinoma in a male breast cyst: a diagnostic challenge.



    		+-nlAnn R Coll Surg Engl 88(5):W3-5 (2006) Sinha S
    191995Management of ductal carcinoma in situ of the breast.



    		+-nlAnn R Coll Surg Engl 77(3):163-7 (1995)
    201954Carcinoma of the breast: a review of the treatment.



    		+-nlAnn R Coll Surg Engl 14(4):215-46 (1954)
    212004Axillary lymph node dissection versus the sentinel lymph node technique in breast cancer.



    		+-nlAnn Surg 240(1):7-8 (2004) Seigler HF
    221998Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.



    		+-nlAnn Surg 227(5):645-51; discussion 651-3 (1998)
    231994Current management of carcinoma of the breast.



    		+-nlAnn Surg 220(2):121-36 (1994)
    241992Current management of male breast cancer. A review of 104 cases.



    		+-nlAnn Surg 215(5):451-7; discussion 457-9 (1992)
    251987Adenoid cystic carcinoma of the breast. Data from the Connecticut Tumor Registry and a review of the literature.



    		+-nlAnn Surg 205(3):295-301 (1987)
    261985Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy.



    		+-nlAnn Surg 201(4):527-32 (1985)
    271964PAGET'S DISEASE OF THE MALE BREAST: A CASE REPORT AND A REVIEW OF THE LITERATURE.



    		+-nlAnn Surg 159(-):305-9 (1964)
    281951The rationale of radical mastectomy; a review.



    		+-nlAnn Surg 133(3):330-43 (1951)
    292009Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients.



    		+-nlBMC Cancer 9():108 (2009) Hoffmann J
    302006Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.



    		+-nlBMC Cancer 6():269 (2006) Nicolini A
    312006Evidence-based risk factors for seroma formation in breast surgery.



    		+-nlJpn J Clin Oncol 36(4):197-206 (2006) Kuroi K
    322010Chemotherapy for breast cancer (Review).



    		+-nlOncol Rep 24(5):1121-31 (2010) Hassan MS
    332010Male breast cancer: risk factors, diagnosis, and management (Review).



    		+-nlOncol Rep 24(5):1115-20 (2010) Johansen Taber KA
    342008Clinical characteristics of small cell carcinoma of the breast.



    		+-nlOncol Rep 19(4):981-5 (2008) Sadanaga N
    352009Optimal use of taxanes in metastatic breast cancer.



    		+-nlCurr Oncol 16(3):8-20 (2009) King KM
    362004Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response.



    		+-nlClin Breast Cancer 5(3):235-8 (2004) Rajan R
    372002Bisphosphonates: biological response modifiers in breast cancer.



    		+-nlClin Breast Cancer 3(3):206-16; discussion 217-8 (2002)
    382001Platinum compounds in the treatment of advanced breast cancer.



    		+-nlClin Breast Cancer 2(3):190-208; discussion 209 (2001)
    392009Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.



    		+-nlAnn Oncol 20(4):615-20 (2009) Falandry C
    402008Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.



    		+-nlAnn Oncol 19(9):1530-9 (2008) Rayson D
    412008Recent advances in adjuvant systemic therapy for early-stage breast cancer.



    		+-nlAnn Oncol 19 Suppl 5():v122-7 (2008) Bedard PL
    422008The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients.



    		+-nlAnn Oncol 19(7):1213-5 (2008) Del Mastro L
    432008Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 19 Suppl 2():ii7-10 (2008) Pestalozzi B
    442008Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 19 Suppl 2():ii11-3 (2008) Kataja V
    452007A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.



    		+-nlAnn Oncol 18(7):1152-8 (2007) Chan A
    462007Lapatinib in breast cancer.



    		+-nlAnn Oncol 18 Suppl 6():vi26-30 (2007) Bilancia D
    472007Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.



    		+-nlAnn Oncol 18(6):977-84 (2007) Valabrega G
    482006Precancerous lesions of the breast.



    		+-nlAnn Oncol 17 Suppl 10():x271-3 (2006) Costa A
    492005Chemotherapy for metastatic breast cancer.



    		+-nlAnn Oncol 16 Suppl 4():iv23-27 (2005) Barni S
    502004Primary chemotherapy for breast cancer: the evidence and the future.



    		+-nlAnn Oncol 15(8):1161-71 (2004) Mano MS
    512003The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.



    		+-nlAnn Oncol 14(5):667-74 (2003) Gogas H
    521967A review of 146 cases of carcinoma of the breast operated on between 1930 and 1943.



    		+-nlBr J Cancer 21(2):260-9 (1967)
    532005A systematic review of taxane-containing regimens for metastatic breast cancer.



    		+-nlBr J Cancer 93(3):293-301 (2005) Ghersi D
    542009New molecular classifications of breast cancer.



    		+-nlCA Cancer J Clin 59(5):303-13 (2009) Cianfrocca M
    552000The diagnosis and management of ductal carcinoma in-situ of the breast.



    		+-nlCA Cancer J Clin 50(3):184-200 (2000)
    561998Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology.



    		+-nlCA Cancer J Clin 48(2):108-28 (1998)
    571998Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology.



    		+-nlCA Cancer J Clin 48(2):83-107 (1998)
    581997Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast.



    		+-nlCA Cancer J Clin 47(1):52-64 (1997)
    591997Tumor-related prognostic factors for breast cancer.



    		+-nlCA Cancer J Clin 47(1):28-51 (1997)
    601995The surgical management of primary invasive breast cancer.



    		+-nlCA Cancer J Clin 45(5):279-88 (1995)
    611995The woman at increased risk for breast cancer: evaluation and management strategies.



    		+-nlCA Cancer J Clin 45(5):263-78 (1995)
    621995Management of ductal carcinoma in situ.



    		+-nlCA Cancer J Clin 45(4):244-53 (1995)
    631995Primary chemotherapy in surgically resectable breast cancer.



    		+-nlCA Cancer J Clin 45(4):227-43 (1995)
    641995Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy.



    		+-nlCA Cancer J Clin 45(4):199-226 (1995)
    651991Cancer of the breast in men.



    		+-nlCA Cancer J Clin 41(6):339-54 (1991)
    661991The role of radiation therapy in the management of primary breast cancer.



    		+-nlCA Cancer J Clin 41(2):85-96 (1991)
    671991The surgical management of primary breast cancer.



    		+-nlCA Cancer J Clin 41(2):71-84 (1991)
    682008Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.



    		+-nlCancer 113(9):2385-97 (2008) Hurvitz SA
    692008The molecular journey from ductal carcinoma in situ to invasive breast cancer.



    		+-nlCancer 112(10):2130-42 (2008) Wiechmann L
    702007Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.



    		+-nlCancer 110(8):1687-96 (2007) Goldstein NS
    712007Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies.



    		+-nlCancer 110(6):1187-94 (2007) Sauer R
    722005Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?



    		+-nlCancer 104(8):1567-74 (2005) Noruzinia M
    732005Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.



    		+-nlCancer 103(9):1778-84 (2005) Collins LC
    742005Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.



    		+-nlCancer 103(4):672-9 (2005) Bria E
    752004The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.



    		+-nlCancer 101(7):1482-9 (2004) Morandi P
    762004Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening.



    		+-nlCancer 100(7):1337-44 (2004) Ernst MF
    772000Pathologic analysis of sentinel lymph nodes in breast carcinoma.



    		+-nlCancer 88(5):971-7 (2000)
    781999Understanding ductal carcinoma in situ: a step in the right direction.



    		+-nlCancer 86(3):375-7 (1999)
    791999Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996.



    		+-nlCancer 85(3):629-39 (1999)
    801998Carcinoma of the breast in males: a multiinstitutional survey.



    		+-nlCancer 83(3):498-509 (1998) Donegan WL
    811998Metaplastic carcinoma of the breast: report of three cases.



    		+-nlCancer 82(6):1082-7 (1998)
    821997The role of histologic grading in the prognosis of patients with carcinoma of the breast: is this a neglected opportunity?



    		+-nlCancer 80(9):1708-16 (1997) Roberti NE
    832010A review of triple-negative breast cancer.



    		+-nlCancer Control 17(3):173-6 (2010) Ismail-Khan R
    842001NCCN: Breast cancer.



    		+-nlCancer Control 8(6 Suppl 2):54-61 (2001)
    851999Ductal Carcinoma In Situ of the Breast.



    		+-nlCancer Control 6(3):264-271 (1999) Dupont EL
    862008Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?



    		+-nlClin Cancer Res 14(21):6725-9 (2008)
    871998Update on endocrine therapy for breast cancer.



    		+-nlClin Cancer Res 4(3):527-34 (1998)
    882009International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.



    		+-nlJ Natl Cancer Inst 101(17):1174-81 (2009) Cardoso F
    892008Anthracyclines in the treatment of HER2-negative breast cancer.



    		+-nlJ Natl Cancer Inst 100(1):2-4 (2008) Paik S
    902009The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.



    		+-nlOncologist 14(4):320-68 (2009) Ross JS
    912008FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.



    		+-nlOncologist 13(10):1114-9 (2008) Ryan Q
    922008Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.



    		+-nlOncologist 13(6):620-30 (2008) Dahabreh IJ
    932008Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.



    		+-nlOncologist 13(5):515-25 (2008) Bullock K
    942007Current treatment and clinical trial developments for ductal carcinoma in situ of the breast.



    		+-nlOncologist 12(11):1276-87 (2007) Boughey JC
    952007Steroid sulfatase: a new target for the endocrine therapy of breast cancer.



    		+-nlOncologist 12(4):370-4 (2007) Stanway SJ
    962007BRCA1, a potential predictive biomarker in the treatment of breast cancer.



    		+-nlOncologist 12(2):142-50 (2007) James CR
    972006Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.



    		+-nlOncologist 11(7):718-31 (2006) Ryan PD
    982006Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.



    		+-nlOncologist 11(7):704-17 (2006) Pietras RJ
    992006Aromatase inhibitors in breast cancer: an overview.



    		+-nlOncologist 11(6):553-62 (2006) Altundag K
    1002006Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.



    		+-nlOncologist 11(6):541-52 (2006) Henry NL
    1012006Benign breast diseases: classification, diagnosis, and management.



    		+-nlOncologist 11(5):435-49 (2006) Guray M
    1022006Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.



    		+-nlOncologist 11 Suppl 1():4-12 (2006) Baselga J
    1032005A review of the diagnosis and management of male breast cancer.



    		+-nlOncologist 10(7):471-9 (2005) Giordano SH
    1042004Recognition and management of hereditary breast cancer syndromes.



    		+-nlOncologist 9(1):13-24 (2004) Thull DL
    1052003Update on the management of inflammatory breast cancer.



    		+-nlOncologist 8(2):141-8 (2003) Cristofanilli M
    1061977Comparative effects of a series of prolactin inhibitors, 17beta-estradiol and 2alpha-methyldihydrotestosterone propionate, on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas.



    		+-nlCancer Res 37(11):3932-8 (1977)
    1072010Histological types of breast cancer: how special are they?



    		+-nlMol Oncol 4(3):192-208 (2010) Weigelt B
    1082005Aromatase inhibitors in the treatment of breast cancer.



    		+-nlEndocr Rev 26(3):331-45 (2005) Brueggemeier RW
    1092008HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.



    		+-nlAm J Clin Pathol 129(6):907-11 (2008) Brunelli M
    1102008HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.



    		+-nlAm J Clin Pathol 129(2):263-73 (2008) Hicks DG
    1112007Breast cancer: origins and evolution.



    		+-nlJ Clin Invest 117(11):3155-63 (2007) Polyak K
    1122008Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.



    		+-nlJ Mol Diagn 10(5):383-95 (2008) Allain DC
    1132007A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.



    		+-nlMayo Clin Proc 82(9):1131-40 (2007) Pruthi S
    1142007A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis.



    		+-nlMayo Clin Proc 82(8):999-1012 (2007) Pruthi S
    1152008Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients.



    		+-nlAJR Am J Roentgenol 191(6):1631-9 (2008) Mathew J
    1162008Spectrum of papillary lesions of the breast: clinical, imaging, and pathologic correlation.



    		+-nlAJR Am J Roentgenol 191(3):700-7 (2008) Muttarak M
    1172001Radioguided sentinel lymph node biopsy in breast cancer surgery.



    		+-nlJ Nucl Med 42(8):1198-215 (2001)
    1182009From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.



    		+-nlRadiographics 29(3):907-31 (2009) Chung EM
    1192009Nipple-areolar complex: normal anatomy and benign and malignant processes.



    		+-nlRadiographics 29(2):509-23 (2009) Nicholson BT
    1202008Rare breast lesions: correlation of imaging and histologic features with WHO classification.



    		+-nlRadiographics 28(5):1399-414 (2008) Irshad A
    1212007Common and unusual diseases of the nipple-areolar complex.



    		+-nlRadiographics 27 Suppl 1():S65-77 (2007) Da Costa D
    1222007Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation.



    		+-nlRadiographics 27 Suppl 1():S53-64 (2007) Doshi DJ
    1232007Breast lesions incidentally detected with CT: what the general radiologist needs to know.



    		+-nlRadiographics 27 Suppl 1():S37-51 (2007) Harish MG
    1242007In vivo proton MR spectroscopy of the breast.



    		+-nlRadiographics 27 Suppl 1():S253-66 (2007) Stanwell P
    1252007Proton (1H) MR spectroscopy of the breast.



    		+-nlRadiographics 27 Suppl 1():S241-52 (2007) Bartella L
    1262007FDG PET, PET/CT, and breast cancer imaging.



    		+-nlRadiographics 27 Suppl 1():S215-29 (2007) Rosen EL
    1272007FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations.



    		+-nlRadiographics 27 Suppl 1():S197-213 (2007) Lim HS
    1282007Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation.



    		+-nlRadiographics 27 Suppl 1():S165-82 (2007) Causer PA
    1292006Imaging characteristics of malignant lesions of the male breast.



    		+-nlRadiographics 26(4):993-1006 (2006) Chen L
    1302004Thoracic manifestations of breast cancer and its therapy.



    		+-nlRadiographics 24(5):1269-85 (2004) Jung JI
    1312004Normal and abnormal US findings at the mastectomy site.



    		+-nlRadiographics 24(2):357-65 (2004) Kim SM
    1322003Missed breast carcinoma: pitfalls and pearls.



    		+-nlRadiographics 23(4):881-95 (2003) Majid AS
    1332002Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.



    		+-nlRadiographics 22(1):5-17 (2002)
    1341998High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer.



    		+-nlRadiographics 18(4):903-12 (1998)
    1351996Lessons from mammographic-histopathologic correlation of large-core needle breast biopsy.



    		+-nlRadiographics 16(5):1111-30 (1996)
    1361990Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer.



    		+-nlRadiographics 10(5):857-70 (1990)
    1372010US of breast masses categorized as BI-RADS 3, 4, and 5: pictorial review of factors influencing clinical management.



    		+-nlRadiographics 30(5):1199-213 (2010)
    1382010Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images.



    		+-nlRadiographics 30(2):533-48 (2010) Santamaria G
    1391999Unusual breast lesions: radiologic-pathologic correlation.



    		+-nlRadiographics 19 Spec No(-):S11-26; quiz S260 (1999)
    1402007Granular cell tumour of the breast: MRI findings and review of the literature.



    		+-nlBr J Radiol 80(960):970-4 (2007) Scaranelo AM
    1412007Mammary angiosarcomas: imaging findings in 24 patients.



    		+-nlRadiology 242(3):725-34 (2007) Yang WT
    1422007Unusual breast cancers: useful clues to expanding the differential diagnosis.



    		+-nlRadiology 242(3):683-94 (2007) Harvey JA
    1432006Phyllodes tumor of the breast: correlation between MR findings and histologic grade.



    		+-nlRadiology 241(3):702-9 (2006) Yabuuchi H
    1442002Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases.



    		+-nlRadiology 223(3):829-38 (2002)
    1452001MR imaging of the breast for the detection, diagnosis, and staging of breast cancer.



    		+-nlRadiology 220(1):13-30 (2001)
    1462000Focal fibrosis of the breast: imaging characteristics and histopathologic correlation.



    		+-nlRadiology 216(1):255-9 (2000)
    1471999Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer.



    		+-nlRadiology 211(3):835-44 (1999)
    1481983Ultrasound, x-ray mammography, and histopathology of cystosarcoma phylloides.



    		+-nlRadiology 146(2):481-6 (1983)
    1492010Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 21 Suppl 5(-):v9-14 (2010)
    1502010BRCA in breast cancer: ESMO Clinical Practice Guidelines.



    		+-nlAnn Oncol 21 Suppl 5(-):v20-2 (2010)
    1512010Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 21 Suppl 5(-):v15-9 (2010)
    1522004Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics.



    		+-nlAnn Oncol 15 Suppl 4(-):iv133-8 (2004)
    1532010Treatment of HER2-overexpressing breast cancer.



    		+-nlAnn Oncol 21 Suppl 7(-):vii36-40 (2010)
    1542010Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?



    		+-nlAnn Oncol 21 Suppl 7(-):vii30-5 (2010)
    1552010Genetic counselling for hereditary predisposition to ovarian and breast cancer.



    		+-nlAnn Oncol 21 Suppl 7(-):vii334-8 (2010)
    1562010What can the pathologist offer for optimal treatment choice?



    		+-nlAnn Oncol 21 Suppl 7(-):vii27-9 (2010)
    1572010Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse.



    		+-nlAnn Oncol 21 Suppl 7(-):vii103-6 (2010)
    1582010Benefits and adverse effects of endocrine therapy.



    		+-nlAnn Oncol 21 Suppl 7(-):vii107-11 (2010)
    1592010Chemotherapy with or without trastuzumab.



    		+-nlAnn Oncol 21 Suppl 7(-):vii112-9 (2010)
    1602007Recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 18 Suppl 2(-):ii9-11 (2007)
    1612007The state of HER-2 status.



    		+-nlAnn Oncol 18(5):813-5 (2007) Di Leo A
    1622009BRCA in breast cancer: ESMO clinical recommendations.



    		+-nlAnn Oncol 20 Suppl 4(-):19-20 (2009)
    1632009Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 20 Suppl 4(-):15-8 (2009)
    1642009Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.



    		+-nlAnn Oncol 20 Suppl 4(-):10-4 (2009)
    1652009Breast carcinoma--rare types: review of the literature.



    		+-nlAnn Oncol 20(11):1763-70 (2009)
    1662010Histological, molecular and functional subtypes of breast cancers.



    		+-nlCancer Biol Ther 10(10):955-60 (2010)
    1672007MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing.



    		+-nlCancer Biol Ther 6(9):1355-7 (2007)
    1682010Cystic masses of the breast.



    		+-nlAJR Am J Roentgenol 194(2):W122-33 (2010)
    1692008Angiosarcoma of the breast.



    		+-nlAJR Am J Roentgenol 190(2):533-8 (2008)
    1702010Cystic breast masses and the ACRIN 6666 experience.



    		+-nlRadiol Clin North Am 48(5):931-87 (2010)
    1712010Ductal carcinoma in situ of the breast: MR imaging findings with histopathologic correlation.



    		+-nlRadiographics 30(6):1673-87 (2010)
    1722010Can MR Imaging contribute in characterizing well-circumscribed breast carcinomas?



    		+-nlRadiographics 30(6):1689-702 (2010)
    1732009Emerging technologies for assessing HER2 amplification.



    		+-nlAm J Clin Pathol 132(4):539-48 (2009)
    1742011Genomic testing and therapies for breast cancer in clinical practice.



    		+-nlAm J Manag Care 17(5 Spec No):e174-81 (2011)
    1752011US insurance program's experience with a multigene assay for early-stage breast cancer.



    		+-nlAm J Manag Care 17(5 Spec No):e194-202 (2011)
    1762006Medical treatment of early breast cancer. I: adjuvant treatment.



    		+-nlBMJ 332(7532):34-7 (2006)
    1772006Medical treatment of early breast cancer. IV: neoadjuvant treatment.



    		+-nlBMJ 332(7535):223-4 (2006)
    1782006Medical treatment of early breast cancer. III: chemotherapy.



    		+-nlBMJ 332(7534):161-2 (2006)
    1792008Gynaecomastia and breast cancer in men.



    		+-nlBMJ 336(7646):709-13 (2008)
    1802009ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.



    		+-nlBiochim Biophys Acta 1796(2):162-75 (2009)
    1812008Overview of breast cancer staging and surgical treatment options.



    		+-nlCleve Clin J Med 75 Suppl 1(-):S10-6 (2008)
    1822008Trends in breast cancer screening and diagnosis.



    		+-nlCleve Clin J Med 75 Suppl 1(-):S2-9 (2008)
    1832006The basal phenotype of BRCA1-related breast cancer: past, present and future.



    		+-nlCell Cycle 5(9):963-7 (2006)
    1842010The Met receptor tyrosine kinase and basal breast cancer.



    		+-nlCell Cycle 9(6):1043-50 (2010)
    1852010Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.



    		+-nlMayo Clin Proc 85(6):560-6; quiz 566 (2010)
    1862009Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.



    		+-nlEndocr Rev 30(1):51-74 (2009)
    1872011Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients.



    		+-nlPLoS One 6(11):e26946 (2011)
    1882010Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.



    		+-nlClin Cancer Res 16(19):4702-10 (2010)
    1892010Metformin: a therapeutic opportunity in breast cancer.



    		+-nlClin Cancer Res 16(6):1695-700 (2010)
    1902008Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.



    		+-nlClin Cancer Res 14(4):961-70 (2008)
    1912010Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.



    		+-nlOncologist 15(5):457-65 (2010)
    1922010Review of the clinical studies using the 21-gene assay.



    		+-nlOncologist 15(5):447-56 (2010)
    1932010Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.



    		+-nlOncologist 15(1):26-36 (2010)
    1942010Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.



    		+-nlOncologist 15(3):216-35 (2010)
    1952009HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.



    		+-nlOncologist 14(8):760-8 (2009)
    1962008Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.



    		+-nlOncologist 13(4):373-81 (2008)
    1972009Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer.



    		+-nlOncologist 14(11):1061-9 (2009)
    1982010Primary systemic chemotherapy for inflammatory breast cancer.



    		+-nlCancer 116(11 Suppl):2821-8 (2010)
    1992010Inflammatory breast cancer--The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007.



    		+-nlCancer 116(11 Suppl):2815-20 (2010)
    2002010Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments.



    		+-nlCancer 116(11 Suppl):2794-805 (2010)
    2012010Gene expression profiling of inflammatory breast cancer.



    		+-nlCancer 116(11 Suppl):2783-93 (2010)
    2022010Targeted therapy in inflammatory breast cancer.



    		+-nlCancer 116(11 Suppl):2758-9 (2010)
    2032010Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge.



    		+-nlCancer 116(11 Suppl):2748-54 (2010)
    2042010Potential impact of tumor registry rule changes for recording inflammatory breast cancer.



    		+-nlCancer 116(11 Suppl):2745-7 (2010)
    2052006Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.



    		+-nlCancer 107(2):221-31 (2006)
    2062011Adjuvant therapy for women over age 65 with breast cancer.



    		+-nlDtsch Arztebl Int 108(21):365-71 (2011)
    2072010A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.



    		+-nlHealth Technol Assess 14(50):1-103 (2010)
    2082009Lapatinib for the treatment of HER2-overexpressing breast cancer.



    		+-nlHealth Technol Assess 13 Suppl 3(-):1-6 (2009)
    2092009Male breast cancer: experience from a Malaysian tertiary centre.



    		+-nlSingapore Med J 50(5):519-21 (2009)
    2102011Diagnosis and local management of breast cancer: part I.



    		+-nlFuture Oncol 7(8):955-7 (2011)
    2112011Diagnosis and local management of breast cancer: part II.



    		+-nlFuture Oncol 7(8):959-61 (2011)
    2122009Current role of breast duct microendoscopy in malignancy.



    		+-nlFuture Oncol 5(10):1523-6 (2009)
    2132002Perspectives on the chemical etiology of breast cancer.



    		+-nlEnviron Health Perspect 110 Suppl 1(-):119-28 (2002)
    2142011False-negative tests in breast cancer management.



    		+-nlNeth J Med 69(7):324-9 (2011)
    2152002Anti-aromatase agents in the treatment and prevention of breast cancer.



    		+-nlCancer Control 9(2 Suppl):2-8 (2002)
    2162002Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.



    		+-nlCancer Control 9(2 Suppl):9-15 (2002)
    2172002The expanding role of epirubicin in the treatment of breast cancer.



    		+-nlCancer Control 9(2 Suppl):16-27 (2002)
    2182007High-risk benign breast lesions: current strategies in management.



    		+-nlCancer Control 14(4):321-9 (2007)
    2192007Management options after prophylactic surgeries in women with BRCA mutations: a review.



    		+-nlCancer Control 14(4):330-7 (2007)
    2202007Breast ductal secretions: clinical features, potential uses, and possible applications.



    		+-nlCancer Control 14(4):350-9 (2007)
    2212005Molecularly targeted therapies for breast cancer.



    		+-nlCancer Control 12(2):73-81 (2005)
    2222010Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.



    		+-nlJ Clin Pathol 63(3):210-9 (2010)
    2232007Non-operative breast pathology: columnar cell lesions.



    		+-nlJ Clin Pathol 60(12):1307-12 (2007)
    2242007Non-operative breast pathology: lobular neoplasia.



    		+-nlJ Clin Pathol 60(12):1321-7 (2007)
    2252007Demystifying basal-like breast carcinomas.



    		+-nlJ Clin Pathol 60(12):1328-32 (2007)
    2262007Non-operative breast pathology.



    		+-nlJ Clin Pathol 60(12):1297-9 (2007)
    2272007Non-operative breast pathology: apocrine lesions.



    		+-nlJ Clin Pathol 60(12):1313-20 (2007)
    2282010Diagnostic evaluation of papillary lesions of the breast on core biopsy.



    		+-nlMod Pathol 23(7):1021-8 (2010)
    2292010Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology.



    		+-nlMod Pathol 23 Suppl 2(-):S1-7 (2010)
    2302010Lobular neoplasia: morphology, biological potential and management in core biopsies.



    		+-nlMod Pathol 23 Suppl 2(-):S14-25 (2010)
    2312010Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale.



    		+-nlMod Pathol 23 Suppl 2(-):S26-32 (2010)
    2322010Clinical applications of breast pathology: management of in situ breast carcinomas and sentinel node biopsy issues.



    		+-nlMod Pathol 23 Suppl 2(-):S33-5 (2010)
    2332010Breast core needle biopsy: issues and controversies.



    		+-nlMod Pathol 23 Suppl 2(-):S36-45 (2010)
    2342010Pathology of hereditary breast cancer.



    		+-nlMod Pathol 23 Suppl 2(-):S46-51 (2010)
    2352010Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.



    		+-nlMod Pathol 23 Suppl 2(-):S52-9 (2010)
    2362010Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.



    		+-nlMod Pathol 23 Suppl 2(-):S60-4 (2010)
    2372010Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation.



    		+-nlMod Pathol 23 Suppl 2(-):S8-13 (2010)
    2382005The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.



    		+-nlMod Pathol 18(10):1305-20 (2005)
    2392008Her2 cross talk and therapeutic resistance in breast cancer.



    		+-nlFront Biosci 13(-):3906-12 (2008)
    2402007The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.



    		+-nlMol Med 13(7-8):396-406 (2007)



    Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

    All data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.